FindTrial
Sign In

Relationship between compliance and curative effect of oral ocitinib in patients with non-small cell lung cancer

Relationship between compliance and curative effect of oral ocitinib in patients with non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078070
Enrollment
Unknown
Registered
2023-11-28
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Oral ocitinib compliance group and poor compliance group:None

Sponsors

The First Affiliated Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for non-small cell lung cancer in the Chinese Medical Association Lung Cancer Clinical Diagnosis and Treatment Guidelines (2018 edition) ; (2) Patients with non-small cell lung cancer who take ocitinib orally; (3) Ages 18-85; (4) The physical status score of the Eastern Cancer Collaboration Group (ECOG) was 0-3, and the life expectancy was > 3 months.

Exclusion criteria

Exclusion criteria: (1) Liver, kidney and other organ dysfunction, mental illness; (2) Patients who are unwilling to undergo follow-up; (3) Patients with other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Medication compliance;PFS;OS;—

Secondary

MeasureTime frame
security;Clinical effect;—

Countries

china

Contacts

Public ContactHongbin Xu

The First Affiliated Hospital of Ningbo University

jiang_rh@126.com+86 189 5178 3095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026